Project Details
Description
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects with Cystic Fibrosis and G551D Mutation.
| Status | Finished |
|---|---|
| Effective start/end date | 9/16/09 → 9/9/12 |
Funding
- VERTEX PHARMACEUTICALS INCORPORATED
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.